The AAPS Journal

, Volume 7, Issue 1, pp E143–E148

Ajulemic acid (IP-751): Synthesis, proof of principle, toxicity studies, and clinical trials

Article

DOI: 10.1208/aapsj070115

Cite this article as:
Burstein, S. AAPS J (2005) 7: E143. doi:10.1208/aapsj070115

Abstract

Ajulemic acid (CT-3, IP-751,1’,1’-dimethylheptyl-Δ8 acid) (AJA) has a cannabinoid-derived structure; however, there is no evidence that it produces psychotropic actions when given at therapeutic doses. In a variety of animal assays, AJA shows efficacy in models for pain and inflammation. Furthermore, in the rat adjuvant arthritis model, it displayed a remarkable action in preventing the destruction of inflamed joints. A phase-2 human trial with chronic, neuropathic pain patients suggested that AJA could become a useful drug for treating this condition. Its low toxicity, particularly its lack of ulcerogenicity, further suggests that it will have a highly favorable therapeutic index and may replace some of the current anti-inflammatory/analgesic medications. Studies to date indicate a unique mechanism of action for AJA that may explain its lack of adverse side effects.

Keywords

ajulemic acidanalgesiaanti-inflammatorycannabinoidIP-751

Copyright information

© American Association of Pharmaceutical Scientists 2005

Authors and Affiliations

  1. 1.Department of Biochemistry and Molecular PharmacologyUniversity of Massachusetts Medical SchoolWorcester